Elevian and Insilico Medicine Collaborates to Develop Therapies Targeting Aging
Shots:
- Elevian collaborated with Insilico to develop and commercialize candidates targeting GDF11 pathway to treat
age-related disorders - The collaboration focuses on the drug discovery and development using Insilico’s generative adversarial networks (GANs) and reinforcement learning (RL) AI technologies to the targets provided by Elevian targeting aging
- GDF11 is a myostatin (GDF8)-homologous protein involved in inhibiting nerve tissue growth and further affecting cellular growth. Additionlaly, Insilico collaborated with Juvenescence Limited & Buck Institute for Research on Aging to discover candidates for for aging
Click here to read full press release/ article | Ref: BusinessWire | Image: Lifeboat